RNA BIOCHEMISTRY IS ONE OF THE MOST PROMISING AREAS OF MEDICINAL INNOVATION
First Health Pharmaceuticals has a leading position in the field of advanced RNA biochemistry. We aim to further develop our portfolio of highly active patented RNA Helicase inhibiting lead compounds and bring revolutionary pharmaceuticals to the market that will offer new hope for patients suffering from some of the most challenging diseases of our time.
First Health Pharmaceuticals developed the first ever generation of Translation Inhibitor antiretroviral compounds effective against HAART resistant HIV strains
The role of DDX3 in breast cancer has been studied most extensively. Our DDX3 Inhibitors were successfully tested on metastatic breast cancer cell lines expressing DDX3
No antivirus was thus far available against Dengue virus, but our anti Dengue lead compound demonstrates excellent antiviral activity combined with very low cytotoxicity
DDX3 inhibition has a mitigating effect on the immune response which is one of the key triggering factors causing Cytokine Storm, suggesting a potential benefit in the treatment of haemorrhagic fever
First Health Pharma prioritizes the development of compounds with optimal physico-chemical profile, from the early phases of drug discovery pipeline, to increase the chances of research project success.
Through the use of proprietary software, statistical analysis tools and machine learning algorithms, First Health Pharmaceuticals brought computer aided drug development to a new level
- July 31, 2018
- First Health, First Health United, HIV/AIDS, In the News, Uncategorized
First Health Pharmaceuticals B.V. has been openly championing LGBTQI rights since its foundation. We reaffirm our commitment against all forms of...
- July 18, 2018
- Cancer, First Health, First Health United, HIV/AIDS, In the News, Uncategorized
First Health Pharmaceuticals and First Health United Foundation are going to participate at AIDS2018, the 22nd International AIDS Conference on HIV and...
- December 1, 2017
- First Health, HIV/AIDS, In the News, RNA Viruses, Uncategorized
Global HIV & AIDS figures According to the latest global statistics on the status of AIDS epidemic, in 2016, 36.7 million...
- November 30, 2017
- First Health United, RNA Viruses, Uncategorized
Setback in Dengue vaccine program highlights the urgent need for effective and free Dengue antiviral agents
Today it was announced that the use of the only approved Dengue vaccine, Dengvaxia, is to be strictly limited due to...
- November 10, 2017
- First Health, HIV/AIDS, In the News, Uncategorized
The biennial International AIDS Conference, AIDS2018, is the world’s biggest healthcare conference and will be held in Amsterdam from July 23rd to 27th, 2018....
- August 28, 2017
- In the News, Uncategorized
NanoDSF and MicroScaleThermophoresis (MST) are two groundbreaking technologies concerning protein-ligand binding assay offered by our development partner Proteros GMBH.